argenx SE ADR
ARGX: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| R?? | LOCK|JM | LOCK|N!P?@yg |
Argenx: Vyvgart Disappointment in Sjogren's Overshadows Emerging FB102 Growth Platform
Argenx shares fell sharply on Oct. 8 after the company discontinued a phase 3 study of Vyvgart in Sjogren's disease due to futility, with Brussels-listed shares down 16% and ADR shares down 12%. Separately, the company reported positive phase 2 topline data for FB102 in celiac disease.
